Second-generation antihistamines in asthma therapy: Is there a protective effect?

American Journal of Respiratory Medicine

Volumn 1, Issue 1, 2002, Pages 27-34

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BROMPHENIRAMINE; BUDESONIDE; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE; CORTICOSTEROID; CYPROHEPTADINE; DESLORATADINE; DRUG METABOLITE; EBASTINE; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; INTERCELLULAR ADHESION MOLECULE 1; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; PLACEBO; PSEUDOEPHEDRINE; TERFENADINE; THEOPHYLLINE;

ALLERGIC RHINITIS; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BASOPHIL; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CARDIOTOXICITY; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; EDEMA; ENANTIOMER; HEART ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; LOWER RESPIRATORY TRACT; MAST CELL; MONOTHERAPY; MUCOSA; MUCUS SECRETION; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; RESPIRATORY EPITHELIUM; REVIEW; RISK FACTOR; SMOOTH MUSCLE CONTRACTION; TISSUE DISTRIBUTION; UPPER RESPIRATORY TRACT;

EID: 0041886532     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03257160     Document Type: Review

References (76)

1. Evans R. Epidemiology and natural history of asthma, allergic rhinitis and atopic dermatitis. In: Middleton Jr E, Reed CE, Ellis EF, editors. Allergy principles and practice. 4th ed. St Louis (MO): Mosby, 1993: 1109-36
2. Simons FER, Simons KJ. Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. Clin Pharmokinet 1991; 21: 372-93
3. Lipworth BJ. Modern drug treatment of chronic asthma. BMJ 1999; 318: 380-4
4. Eggleston PA. Upper airway inflammatory diseases and bronchial hyperresponsiveness. J Allergy Clin Immunol 1988; 81: 1036-41
5. Holgate ST, Finnerty JP. Antihistamines in asthma. J Allergy Clin Immunol 1989; 83: 537-47
6. Meltzer EO. To use or not to use antihistamines in patients with asthma [editorial]. Ann Allergy 1990; 64: 183-6
7. Akagi K, Townley RG. Spontaneous histamine-release and histamine content in normal subjects and subjects with asthma. J Allergy Clin Immunol 1989; 83: 742-9
8. Casale TB, Wood D, Richerson HB. Direct evidence of a role for mast cells in pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987; 80: 1507-11
9. Casale TB. Wood D. Richerson HB. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 1987; 79: 1197-203
10. Malick A, Grant J. Antihistamines in the treatment of asthma. Allergy 1997; 52 Suppl. 34: 55-66
11. Walsh GM, Annunziato L. Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001; 61: 207-36
12. Church MK. H1 antihistamines and inflammation [editorial]. Clin Exp Allergy 2001; 31: 1341-3
13. Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy 1999; 29: 1593-6
14. Wood-Baker R. Holgate ST. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993: 91: 1005-14
15. Wood-Baker R, Holgate ST. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine- and methacholine-induced bronchoconstriction in patients asthma. Agents Actions 1990 Apr; 30 (1-2): 284-6
16. Chyrek-Borowska S, Siergiejko Z, Michalska I. The effects of a new generation of H1 antihistamines (cetirizine and loratadine) on histamine release and the bronchial response to histamine in atopic patients. J Investig Allergol Clin Immunol 1995; 5 (2): 103-7
17. Ghosh SK, Rafferty P. De Vos C, et al. Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma. Clin Exp Allergy 1993; 23: 524-7
18. Busse WW, Middleton E, Storms W, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 1996; 153: 122-7
19. Chervinsky P, Grossman J, Freitag JJ. Duration of action of a single dose of azelastine in patients with chronic asthma. J Asthma 1995; 32: 141-5
20. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. J Allergy Clin Immunol 1996; 97: 1218-24
21. Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999; 36: 453-96
22. Umetsu DT, DeKruyff RH. Th1 and Th2 CD4+ cells in human allergic diseases. J Allergy Clin Immunol 1997; 100: 1-6
23. Hoshino M, Nakamura Y. The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int Arch Allergy Immunol 1997; 114: 285-92
24. Wasserfallen JB, Leuenberger P, Pecoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993; 91: 1189-97
25. Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on the early and late asthmatic responses to allergen and the associated increases in airways responsiveness. Clin Exp Allergy 1996; 26: 909-17
26. Bruttmann G, Pedrali P, Arendt C, et al. Protective effect of cetirizine in patients suffering from pollen asthma. Ann Allergy 1990; 64: 224-8
27. Bousquet J, Emonot A, Germouty J, et al. Double-blind multicenter study of cetirizine in grass pollen-induced asthma. Ann Allergy 1990; 65: 504-58
28. Dijkman JH, Hekking PR, Molkenboer JF, et al. Prophylactic treatment of grass pollen-induced asthma with cetirizine. Clin Exp Allergy 1990; 20: 483-90
29. Rafferty P, Ghosh SK, de Vos C, et al. Effect of oral and inhaled cetirizine in allergen-induced bronchoconstriction. Clin Exp Allergy 1993; 23: 528-31
30. Kopferschmitt-Kubler MC, Couchot A, Pauli G. Evaluation of the effect of oral cetirizine on antigen-induced immediate asthmatic response. Ann Allergy 1990; 65: 501-53
31. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomised, placebo controlled trial. J Allergy Clin Immunol 1995; 95: 923-32
32. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440-6
33. Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol and both together versus placebo in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 96: 174-81
34. Kjellman NI. Is there a place for antihistamines in the treatment of perennial asthma? Pediatr Allergy Immunol 1993; 4 Suppl. 4: 38-43
35. Aubier M, Neukirch C, Peiffer C, et al. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 2001; 56: 35-42
36. Kroll VM, Nothofer B, Werdermann K. Allergic bronchial asthma treated with loratadine. Fortschr Med 1993; 111: 76-8
37. Dirksen A, Engel T, Frolund L, et al. Effect of a non-sedative antihistamine (loratadine) in moderate asthma. A double-blind, controlled clinical crossover trial. Allergy 1989; 44: 566-71
38. Ekstrom T, Osterman K, Zetterstrom O. Lack of effect of loratadine on moderate to severe asthma. Ann Allergy Asthma Immunol 1995; 75 (3): 287-98
39. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100: 781-8
40. Rafferty P, Jackson L, Smith R, et al. Terfenadine, a potent antihistamine H1-receptor antagonist in the treatment of grass pollen-sensitive asthma. Br J Pharmacol 1990; 30: 229-35
41. Taytard A, Beaumont D, Pujet JC, et al. Treatment of bronchial asthma with terfenadine; a randomised controlled trial. Br J Pharmacol 1987; 24: 743-6
42. Simons FER, Kesselman MS, Giddins NG, et al. Astemizole-induced torsade de pointes [letter]. Lancet 1988: II (8611): 624
43. Davies AJ, Harinda V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose [letter]. BMJ 1989; 298: 325
44. Honig P, Baraniuk JN. Adverse effects of H1-receptor antagonists in the cardiovascular system. In: Simons FER, editor. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker Inc., 1996: 383-412
45. Horiguchi T. Tachikawa S, Kasahara J, et al. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin Drug Invest 1999; 17: 435-40
46. Mygind N, Dahl R, editors. The nose and the paranasal sinuses in asthma. Allergy 1999; 54 Suppl. 57: 14-25
47. Leurs R, Smit MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther 1995; 66: 413-63
48. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55: 269-74
49. McCellan K, Jarvis B. Desloratadine. Drugs 2001; 61: 789-96
50. Devalia JL. De Vos C, Hanotte F, et al. A randomised double-blind crossover comparison among cetirizine, levocetirizine and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50-7
51. Wang DY, Hanotte F, De Vos C, et al. Effect of cetirizne, levocetirizine and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001; 56: 339-43
52. Brannan JD, Anderson SD, Gomes K, et al. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420-5
53. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal seasonal allergic rhinitis and asthma. Allergy 2001; 56 Suppl. 65: 21-7
54. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369-77
55. Volovitz B, Varsano I, Cumella JC, et al. Efficacy and safetey of ketotifen in young children with asthma. J Allergy Clin Immunol 1988; 81: 526-30
56. Kjellman NIM. Is there a place for antihistamines in the treatment of perennial asthma? Ped Allergy Immunol 1993; 4 Suppl. 4: 38-43
57. Wahn U, Bergmann R, Kulig M, et al. The natural course of sensitisation and atopic disease in infancy and childhood. Pediatr Allergy Immunol 1997; 8 (10 Suppl.): 16-20
58. Iikura Y, Naspitz CK, Mikawa H. Prevention of asthma by ketotifen in infants with atopic dermatits, Ann Allergy 1992; 68: 233-6
59. Passalacqua G, Bousquet J, Bachert C, et al. The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy 1996; 51: 666-75
60. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine on this progression in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998; 9: 116-24
61. Simons FER. Prospective long term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J Allergy Clin Immunol 1999; 104: 433-40
62. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intracellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. J Biol Chem 1999; 274: 9707-20
63. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95: 612-21
64. Ciprandi G, Buscaglia S, Pronzato C, et al. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ann Allergy 1995; 75: 446-52
65. Ciprandi G, Buscaglia S, Marchesi E, et al. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Appl Immunol 1994; 100: 185-9
66. Ciprandi G, Buscaglia S, Iudice A, et al. Protective effect of terfenadine at different dosages on conjunctival provocation test. Allergy 1992; 47: 309-12
67. Fasce L, Ciprandi G, Pronzato C, et. al. Cetirizine reduces ICAM-1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996; 109: 272-6
68. Papi A, Nikolaos G, Papadopoulos NG, et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule-1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001; 108: 221-8
69. Arnold R, Rihoux JP, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelia] cells (A549). Clin Exp Allergy 1999; 29: 1681-91
70. Doull IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: radomised double blind placebo contolled trial. BMJ 1997; 315: 858-62
71. Diamant Z, Sampson AP. Anti-inflammatory effects of leukotriene modulators. Clin Exp Allergy 1999; 29 (11): 1449-53
72. Lipworth BJ. Leukotriene receptor antagonists. Lancet 1999; 353: 57-62
73. Reicin A, White R, Weinstein SF, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000; 160: 2481-8
74. Roquet A, Dahen B, Kumlin M. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Resp Crit Care Med 1997; 155: 1856-63
75. Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of mediator blockade versus topical crticosteroids in allergic rhinitis and asthma. Am J Resp Crit Care Med 2000; 162: 1297-301
76. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonist in seaonal allergic rhinitis. Clin Exp Allergy 2000; 31: 61-8